1. ARHGEF38 as a novel biomarker to predict aggressive prostate cancer
- Author
-
Xianqin Zhang, Geli Liu, Longke Ran, Wanfeng Zhang, Fangzhou Song, Aixiang Wang, Song Jing, Wang Sen, Yujing Wang, and Kun Liu
- Subjects
0301 basic medicine ,PCa ,lcsh:QH426-470 ,urologic and male genital diseases ,Biochemistry ,Article ,Metastasis ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,medicine ,Gleason score ,Molecular Biology ,Gene ,Genetics (clinical) ,lcsh:R5-920 ,Microarray analysis techniques ,business.industry ,Cell Biology ,Hyperplasia ,medicine.disease ,Immunohistochemistry ,lcsh:Genetics ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cancer research ,Biomarker (medicine) ,Kaplan–Meier survival ,Guanine nucleotide exchange factor ,business ,lcsh:Medicine (General) - Abstract
Prostate cancer (PCa) metastasis is considered the leading cause of cancer death in males. Therapeutic strategies and diagnosis for stage-specific PCa have not been well understood. Rho guanine nucleotide exchange factor 38 (ARHGEF38) is related to tumor cell polarization and is frequently expressed in PCa. Microarray data of PCa were downloaded from GEO and TCGA databases. A total of 243 DEGs were screened, of which, 32 genes were upregulated. The results of enrichment analysis showed the participation of these DEGs in the tumor cell metastasis pathway. ARHGEF38 was significantly up-regulated in the four most prevalent cancers worldwide (p
- Published
- 2019